Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMET-HF
CTR20260596Phase 3Active
- Sponsor
- Cytokinetics
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of omecamtiv mecarbil in heart failure with reduced ejection fraction (HFrEF), sponsored by Cytokinetics. Started Jun 2026; status: active.
02
Drugs
omecamtiv mecarbil
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on CTR20260596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260596.